
ODTX Stock Forecast & Price Target
ODTX Analyst Ratings
Bulls say
Odyssey Therapeutics is a strong contender with a diverse and promising pipeline of treatments for inflammatory and immune diseases including OD-001 for IBD. With a target availability in the US and EU by 2030-2031, OD-001 has low risk of side effects and potential for fast and effective treatment. The collaboration with Terray on a new treatment adds to the company's potential for growth and success in the market.
Bears say
Odyssey Therapeutics is facing a negative outlook due to several factors. Firstly, their lead asset, OD-001, has a competitive market with multiple other drugs targeting the same indications, making it difficult for them to stand out. Additionally, their pipeline is still in early stages of development and it will be several years before they have a potential candidate in the market. Furthermore, the company's financials show a decrease in revenue and an increase in expenses, which may impact their ability to fund their research and development efforts in the future.
This aggregate rating is based on analysts' research of Odyssey Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ODTX Analyst Forecast & Price Prediction
Start investing in ODTX
Order type
Buy in
Order amount
Est. shares
0 shares